Filing Details

Accession Number:
0000899243-20-018398
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-02 20:56:47
Reporting Period:
2020-07-02
Accepted Time:
2020-07-02 20:56:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631574 Wave Life Sciences Ltd. WVE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1657710 Paul Bolno C/o Wave Life Sciences Ltd.,
733 Concord Ave.
Cambridge MA 02138
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2020-07-02 4,509 $10.82 315,249 No 4 S Direct
Ordinary Shares Disposition 2020-07-02 43,068 $10.26 272,181 No 4 S Direct
Ordinary Shares Acquisiton 2020-07-02 100,000 $2.48 372,181 No 4 M Direct
Ordinary Shares Disposition 2020-07-02 4,079 $10.91 368,102 No 4 S Direct
Ordinary Shares Disposition 2020-07-02 95,921 $10.27 272,181 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Option (right to buy) Disposition 2020-07-02 100,000 $0.00 100,000 $2.48
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
222,778 2025-03-10 No 4 M Direct
Footnotes
  1. Consists of the sale of shares that were issued upon the vesting of restricted share units. The sale was effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.78 to $11.12 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  3. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $9.77 to $10.77 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  4. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  5. These share options are fully vested.